Paralysis
Also known as: Hemiplegia, Palsy, Paraplegia, Quadriplegia
Methodology & AI Transparency ⓘ
Paralysis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Paralysis is the loss of muscle function in part of your body.
- 2 Real-world patient consensus: Synonyms for Paralysis (G82.20): Hemiplegia, Palsy, Paraplegia (Brain & Neurology).
- 3 Typical cash cost range: Primary evaluation for Paralysis incorporates comprehensive cranial [Paralysis G82.20] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Paralysis: maintaining HbA1c & Blood in Paralysis (G82.20: Pressure Neuro-Targets) within BP < 120/75 mmHg; HbA1c < 5.7% (G82.20).
Ask our AI Specialists anything about Paralysis
What Is Paralysis?
Paralysis is the loss of muscle function in part of your body. It happens when something goes wrong with the way messages pass between your brain and muscles. Paralysis can be complete or partial. It can occur on one or both sides of your body. It can also occur in just one area, or it can be widespread. Paralysis of the lower half of your body, including both legs, is called paraplegia. Paralysis of the arms and legs is quadriplegia. Most paralysis is due to strokes or injuries such as spinal cord injury or a broken neck.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Paralysis (code G82.20) is central or peripheral in Paralysis (G82.20: neuronal conduction disruption), Cross-referenced with NIH MeSH (Paralysis), which Neurology, Stroke & Movement Disorders clinicians address while surveilling HbA1c & Blood in Paralysis (G82.20: Pressure Neuro-Targets) (BP < 120/75 mmHg; HbA1c < 5.7% (G82.20)).
Common Symptoms & Clinical Signs
- • Nerve diseases such as amyotrophic lateral sclerosis
- • Autoimmune diseases such as Guillain-Barre syndrome
- • Presentation of Paralysis (G82.20): focal motor weakness, in Paralysis (G82.20: resting or action)
- • Secondary Paralysis clinical sign: episodic vertigo, imbalance, in Paralysis (G82.20: coordination drift, or)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Paralysis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G82.20 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Neurology, Stroke & Movement Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: HbA1c & Blood in Paralysis (G82.20: Pressure Neuro-Targets) | BP < 120/75 mmHg; HbA1c < 5.7% (G82.20) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Paralysis (G82.20: & Methylmalonic Acid) | B12 > 500 pg/mL; MMA < 240 nmol/L (G82.20) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Carotid Duplex / in Paralysis (G82.20: Cerebral Perfusion) | No hemodynamically significant stenosis (G82.20) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Paralysis
Treatment selection for Paralysis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Paralysis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Siponimod: Disentangling disability and relapses in secondary progressive By controlling the confounding impact of on-study relapses on confirmed disability progression, these statistical approaches provide a methodological framework to assess treatment effects on disability progression in relapsing... Multiple sclerosis (Houndmills, Basingstoke, England) • 2021-09-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33205682 ↗ |
| New Insights on Postoperative C5 Palsy after Anterior or Posterior Decompression for Degenerative: What a 283-Participant Study Found The odds of postoperative C5 palsy are significantly higher after posterior decompression compared to anterior decompression for DCM. Spine • 2024-10-15 • Phase III Randomized Trial | N = 283 | 87/100 | PMID 38616732 ↗ |
| Can This Approach Help? Inside the Latest Research on Laryngeal Reinnervation vs Type I Thyroplasty in Unilateral Vocal Fold Paralysis The results from this study have provided us with the assurance that conducting an adequately powered randomized controlled clinical trial of laryngeal reinnervation versus type I thyroplasty for adults with UVFP in the UK is... The Laryngoscope • 2025-09-15 • Phase III Randomized Trial | N = 12 | 82/100 | PMID 40323143 ↗ |
| Can This Approach Help? Inside the Latest Research on An exposure-response analysis of ponesimod clinical efficacy in a randomized No significant baseline covariates affected the ponesimod effects and, consequently, dosage adjustments are not warranted by these analyses. CPT: pharmacometrics & systems pharmacology • 2022-10-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 36047474 ↗ |
Paralysis Patient Community & “People Like Me” Threads
Filter Paralysis community threads and patient logs by age, biological sex, dosage, and treatment duration.